Harpoon Therapeutics, Inc. Common Stock
HARP
HARP was delisted on the 8th of March, 2024.
44 hedge funds and large institutions have $12M invested in Harpoon Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 6 closing their positions.
889% more call options, than puts
Call options by funds: $89K | Put options by funds: $9K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
4% less funds holding
Funds holding: 46 → 44 (-2)
7% less capital invested
Capital invested by funds: $12.9M → $12M (-$960K)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lion Point Capital
New York
|
+$199K |
| 2 |
Barclays
London,
United Kingdom
|
+$18.7K |
| 3 |
Renaissance Technologies
New York
|
+$11.9K |
| 4 |
Jane Street
New York
|
+$11.6K |
| 5 |
HF
HRT Financial
New York
|
+$7.53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$337K |
| 2 |
B
Bailard
Foster City,
California
|
-$47K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$40.1K |
| 4 |
BlackRock
New York
|
-$38.8K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$32.3K |
HARP Hedge Fund Activity: Q2 2023 in Review
44 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q2 2023, worth a combined $12M — down 7.4% from $12.9M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of HARP and 4 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 10 added.
The largest buyer was Lion Point Capital, adding an estimated $199K. The largest seller was Millennium Management, cutting an estimated $337K.
- 44 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q2 2023, down from 46 in Q1 2023.
- Funds reported $12M of Harpoon Therapeutics, Inc. Common Stock stock for Q2 2023, down 7.4% quarter-over-quarter.
- 4 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q2 2023 and 6 closed out, a net change of -2 holders.
- The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q2 2023 was Lion Point Capital, an estimated $199K added.
- The largest Harpoon Therapeutics, Inc. Common Stock seller in Q2 2023 was Millennium Management, an estimated $337K sold.
Based on aggregated 13F filings for Q2 2023.